Concert Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543

November 3rd, 2020

Concert Pharmaceuticals has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP‑543, in adult patients with moderate to severe alopecia areata.

CTP-543, an oral selective inhibitor of Janus kinases JAK1 and JAK2, is in clinical development for the treatment of moderate to severe alopecia areata. CTP-543 is an investigational drug and has not been approved by the FDA or any regulatory authority for any use.

For more information about the THRIVE-AA1 study, please visit:

Back to Top